FCCC

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Monday, February 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

Morgan Olson and EAVX celebrate development milestone in next-generation PROXIMA step van with Freightliner Custom Chassis Corp.

Retrieved on: 
Wednesday, March 6, 2024
Trucking, Automotive, Automotive Manufacturing, General Automotive, Logistics, Supply Chain Management, Transport, Manufacturing, Chassis, EV, Morgan Olson, Multimedia, PROXIMA, Peter Hancock (professor), Electronics, ICE, Digital, Risk, Safety, FCCC

Morgan Olson, LLC (Morgan Olson) has achieved another innovation milestone in developing the next-generation walk-in step van: Proxima.

Key Points: 
  • Morgan Olson, LLC (Morgan Olson) has achieved another innovation milestone in developing the next-generation walk-in step van: Proxima.
  • This version of Proxima has evolved with a new, radically streamlined body design by J.B. Poindexter & Co., Inc. d/b/a EAVX (EAVX) – the innovation hub for J.B. Poindexter & Co., Inc. (JBPCO).
  • The EV and ICE versions of Proxima introduced at Work Truck Week are riding on Freightliner Custom Chassis Corp. (FCCC) products.
  • “As long-time partners with Morgan Olson, we are thrilled to work with them and the EAVX team on the new Proxima,” said Jeff Sather, President and CEO of FCCC.

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Retrieved on: 
Friday, October 27, 2023
Research, ORY, Fruit, DMC, Food, Deficit spending, Risk, Medicine, ECNP, Schizophrenia, Platinum, ICMJE recommendations, SCLC, Charcot–Marie–Tooth disease, Sciatic nerve, Psychotherapy, Paclitaxel, NET, FCCC, MRD, Safety, EVOLUTION, BPD, Kabuki syndrome, Patient, Borderline personality disorder, ALS, Fox Chase Cancer Center, Genomics, Human, Duration, Glomus tumor, Measure (mathematics), Clinical trial, Dor, DSM-IV codes, Animal, European College of Neuropsychopharmacology, LSD1, FMS, CMT, FDA, IND, Innovation, ISIN, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, HOPE, AML, Failure, Medical device, Pharmaceutical industry, Nursing, Cryptocurrency, EU, Science

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.
  • The company has started a structured dialogue with corporate pharma to identify a suitable partner to move forward the asset to Phase III, pending positive results.
  • General and administrative expenses were $0.7 and $2.9 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.3 million for the quarter and nine months ended September 30, 2022.
  • Net losses were $0.8 and $3.4 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.9 million for the quarter and nine months ended September 30, 2022.

ORYZON to Provide Corporate Progress Updates at Several Events in October

Retrieved on: 
Monday, October 2, 2023
Borderline personality disorder, Genomics, ESMO, The Yale Club of New York City, Jefferies, Kendall Square, Oncology, Fox Chase Cancer Center, CNS, Congress, European College of Neuropsychopharmacology, ORY, FCCC, ISIN, Roth Capital Partners, ECNP, European Society for Medical Oncology, Conference, Pharmaceutical industry, Cryptocurrency

Oryzon will participate in the East-West Biopharma Summit, which will be held on October 2-4 in Kendall Square, Cambridge Mass.

Key Points: 
  • Oryzon will participate in the East-West Biopharma Summit, which will be held on October 2-4 in Kendall Square, Cambridge Mass.
  • (USA), and virtually.
  • The company will provide a corporate update and will also hold one-on-one meetings with US and Chinese pharmaceutical companies and investors.
  • Click on link for more info about the ESMO 2023 congress

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023

Retrieved on: 
Wednesday, May 10, 2023
Medicine, HOPE, Genomics, Glomus tumor, DSM-IV codes, Hospital, Patient, Borderline personality disorder, R, ALS, Charcot–Marie–Tooth disease, Columbia University, LSD1, Human, IDMC, Platinum, Innovation, Research, NET, CMT, Kabuki syndrome, Phase, FDA, IND, Conference, Safety, Duration, Schizophrenia, Seaver Autism Center, Measure (mathematics), Mental health, Deficit spending, ORY, FCCC, Dor, FMS, Hospital Universitario La Paz, BPD, Fox Chase Cancer Center, Clinical trial, Paclitaxel, CNS, Icahn School of Medicine at Mount Sinai, Hospital das Clínicas, AML, Mount Sinai Hospital, Spectrum, ISIN, ICMJE recommendations, Treatment, Pharmaceutical industry, Nursing, Video game, Science, SCLC

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon has made strong clinical progress in the first quarter this year.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon has made strong clinical progress in the first quarter this year.
  • Research and development (R&D) expenses were $4.4 million for the quarter ended March 31, 2023, compared to $4.2million for the quarter ended March 31, 2022.
  • General and administrative expenses were $1.2 million for the first quarter ended March 31, 2023, compared to $1.3 million for the first quarter ended March 31, 2022.
  • Net losses were $1.4 million for the first quarter ended March 31, 2023, compared to $1.7 million for the first quarter ended March 31, 2022.

ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

Retrieved on: 
Wednesday, January 18, 2023
NEC Laboratories America, Prognosis, LSD1, Cancer, AML, Acute myeloid leukemia, Phases of clinical research, Assistant Chief of the Air Staff, Safety, Azacitidine, MD, FDA, Squamous cell carcinoma, ALICE, Hematological Cancer Research Investment and Education Act, Genomics, B cell, ASH, NETS, Patient, Survival, Prevalence, ORY, Fox Chase Cancer Center, FCCC, Research, ORR, ISIN, Paclitaxel, Gastrointestinal tract, NEC, Pharmaceutical industry, SCLC, EU

The trial will assess the safety and efficacy of iadademstat in combination with paclitaxel in patients with relapsed/refractory small cell lung cancer or extrapulmonary high grade NECs.

Key Points: 
  • The trial will assess the safety and efficacy of iadademstat in combination with paclitaxel in patients with relapsed/refractory small cell lung cancer or extrapulmonary high grade NECs.
  • Neuroendocrine neoplasms are rare and heterogeneous cancers arising from neuroendocrine cells, representing 0.5% of all newly diagnosed malignancies, with a prevalence of 100,000 cases in the US.
  • Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.
  • Iadademstat has orphan drug designation for SCLC in the US and for AML in the US and EU.

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Retrieved on: 
Wednesday, November 9, 2022
IND, Communication, Research, CNMV, Development, Sale, Person, NEC Laboratories America, Survival, Fox Chase Cancer Center, CRADA, Associate, Squamous cell carcinoma, Phase II, NETS, Forward-looking statement, Prevalence, Azacitidine, B cell, ISIN, FLT3, Prospectus, FCCC, Mercado, Cancer, Gastrointestinal tract, AML, Patient, MD, NCI, NET, Investigational New Drug, Cooperative research and development agreement, Hematological Cancer Research Investment and Education Act, Medulloblastoma, EHA, Acute myeloid leukemia, NEC, Mission statement, Public expenditure, Growth, FDA, GLOBE, Carcinoma, ORY, ESMO, Wilms' tumor, Spanish, Safety, LSD1, Genomics, ALICE, Prognosis, Pharmaceutical industry, SCLC, EU

Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.

Key Points: 
  • Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.
  • Response rates for NECs and SCLC in second line are generally less than 5% and 20%, respectively, and survival is measured in months.
  • There are very few treatment options for these patients and even fewer trials, which makes this effort even more important.
  • In total iadademstat has been dosed so far to more than 100 cancer patients in four clinical trials.

BIO-key International Joins the AWS Partner Network

Retrieved on: 
Tuesday, June 21, 2022
Zero, Solution, Education, Industry, Security (finance), The Act, COVID-19, Risk, Allan Hancock College, Annual report, Identity, Amazon, SSO, CIAM, Government, Company, U.S. Securities and Exchange Commission, Health, Member of the Scottish Parliament, Micro ISV, Private Securities Litigation Reform Act, FCCC, Growth, Information technology, Program, General manager, NASDAQ, APN, Maintenance, Bell–LaPadula model, Amazon Web Services, IBB, Information Technology Services Agency, History, MFA, Access management, Coronavirus, Identity management, As a service, AWS, International, IAM, Organization, GLOBE, Online shopping, Video game console, WALL

The AWS ISV Accelerate Program will provide BIO-key co-sell support and benefits to connect with AWS field sellers globally, who service millions of active AWS customers.

Key Points: 
  • The AWS ISV Accelerate Program will provide BIO-key co-sell support and benefits to connect with AWS field sellers globally, who service millions of active AWS customers.
  • Co-selling provides better customer outcomes and assures mutual commitment from AWS and AWS partners like BIO-key.
  • As part of the Amazon Partner Network, BIO-key will help customers move identity management to the cloud with greater predictability, simplicity and affordability.
  • We are pleased to expand our ongoing relationship with AWS through the AWS Partner Network, said Mark Cochran, President of PortalGuard, BIO-key.

Allison Transmission Announces Collaboration with Freightliner Custom Chassis Corporation on Walk-In Van Program

Retrieved on: 
Wednesday, March 9, 2022
Other Manufacturing, Technology, Automotive, General Automotive, Security, Automotive Manufacturing, Other Automotive, Software, Manufacturing, Hardware, Allison Transmission, Industry, The World's Work, United Kingdom, Dealer, Product, Mining, Chassis, Allison, Control, Multimedia, Efficiency, ALSN, NYSE, DTG, GM, HP, FCCC, Series, Â, Solution, Torque, Transport, Western Star, Product engineering, Daimler Trucks North America, Video game console, Rail transport, Freightliner, Allison Transmission, Freightliner Custom Chassis Corporation (FCCC), ALLISON TRANSMISSION, FREIGHTLINER CUSTOM CHASSIS CORPORATION (FCCC)

Allison Transmission is pleased to announce that uprate variants of the Allison 1000 Series and 2000 Series transmissions will be integrated into Freightliner Custom Chassis Corporations (FCCC) new powertrain combination for its MT walk-in van chassis.

Key Points: 
  • Allison Transmission is pleased to announce that uprate variants of the Allison 1000 Series and 2000 Series transmissions will be integrated into Freightliner Custom Chassis Corporations (FCCC) new powertrain combination for its MT walk-in van chassis.
  • View the full release here: https://www.businesswire.com/news/home/20220309005309/en/
    Uprate variants of Allison Transmission's 1000 Series and 2000 Series, equipped with its next-generation electronic controls platform, will be integrated into Freightliner Custom Chassis Corporations new powertrain combination for its MT walk-in van chassis.
  • These new Allison transmissions will provide a number of important enhancements and features to the next generation of our MT chassis.
  • Freightliner Custom Chassis Corp. (FCCC) is a leading manufacturer of gas, diesel and alternative-fuel chassis for the medium-duty pick-up and delivery markets.

Daimler Truck North America CEO to Provide Clean Truck Update during Keynote at 2022 Advanced Clean Transportation (ACT) Expo

Retrieved on: 
Wednesday, March 9, 2022
ACT, Industry, OEM, DTNA, Gladstein, Class, NextEra Energy Resources, Adoption, Carbon, FCC, Propane, GLOBE, Long Beach Convention and Entertainment Center, FCCC, Acceleration, Technology, Thomas Built Buses, Transport, Ownership, GNA, CEO, Daimler Trucks North America, Renewable energy, Video game, Freightliner

SANTA MONICA, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Organizers of the Advanced Clean Transportation ( ACT ) Expo, North Americas largest advanced transportation technology and clean fleet event, today announced John OLeary, president and CEO of Daimler Truck North America (DTNA), as the keynote speaker at the 11th annual show, taking place at the Long Beach Convention Center in Southern California from May 9-12, 2022.

Key Points: 
  • SANTA MONICA, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Organizers of the Advanced Clean Transportation ( ACT ) Expo, North Americas largest advanced transportation technology and clean fleet event, today announced John OLeary, president and CEO of Daimler Truck North America (DTNA), as the keynote speaker at the 11th annual show, taking place at the Long Beach Convention Center in Southern California from May 9-12, 2022.
  • DTNA is North Americas largest manufacturer of Class 5-8 commercial vehicles and aims to offer an exclusively zero-emission vehicle product line by 2039.
  • The four-day, fleet-focused agenda at ACT Expo will spotlight the incredible acceleration taking place across the advanced transportation and clean energy sectors.
  • ACT Expo is North Americas largest conference and expo showcasing real-world application of the latest transportation technologies, drivetrains, and clean fuels.